The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company. At the moment, MindMed has sufficient resources to endure for at least a few years. At the end of March it had nearly $238 million in cash, cash equivalents, and short-term investments, which wasn't too much less than the previous quarter's $245 million. According to management, this plus monies for the expected achievement of certain ...